Update 2021: COVID-19 aus Sicht der Infektiologie

Aus Sicht der Infektiologie gab es seit Januar 2020 herausragende Erkenntnisse, die weit über den Wissensgewinn über SARS-CoV-2 hinausgehen und uns hoffentlich in der Bewältigung zukünftiger Pandemien helfen werden. Positiv hervorzuheben sind das verstärkte öffentliche Bewusstsein für Infektionsepidemiologie und -krankheiten, der immunologische Wissensgewinn und die erfolgreiche Nutzung bestehender Plattformen und Technologien zur Impfstoffentwicklung. Dieser Beitrag zeigt eine persönliche Auswahl interessanter Entwicklungen der letzten Monate.

Abstract

From an infectious disease perspective, there have been outstanding findings since January 2020 far beyond the knowledge gained about SARS-CoV, which hopefully will help us to manage future pandemics. Positive highlights include the increased public awareness of infectious disease epidemiology, the increase in immunological knowledge, and the successful use of existing vaccine development platforms and technologies. This article presents a personal selection of interesting developments in recent months.

Schlüsselwörter

COVID-19 - Schützende Immunität - Long COVID - Mutationen - sozioökonomische Deprivation

Key words

COVID-19 - protective immune response - long COVID - mutations - socioeconomic deprivation

Publication History

Article published online:
13 July 2021

• Literatur

• 1 Hoebel J, Michalski N, Wachtler B. et al. Socioeconomic differences in the risk of infection during the second SARS-CoV-2 wave in Germany. Dtsch Aerzteblatt Online 2021; 49: 2020-2021
• 2 Dan JM, Mateus J, Kato Y. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (80-) 2021; 371: 1-23
• 3 Dagan N, Barda N, Kepten E. et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021; 384: 1412-1423
• 4 Bastard P, Rosen LB, Zhang Q. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (80-) 2020; 370
• 5 López-León S, Wegman-Ostrosky T, Perelman C. et al. More than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis. SSRN Electron J 2021; 1-14
• 6 Ahmed M, Advani S, Moreira A. et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine 2020; 26: 100527 DOI: 10.1016/j.eclinm.2020.100527.
• 7 Lauring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2 – What Do They Mean?. JAMA - J Am Med Assoc 2021; 325: 529-531
• 8 Weinreich DM, Sivapalasingam S, Norton T. et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med 2021; 384: 238-251
• 9 Polack FP, Thomas SJ, Kitchin N. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383: 2603-2615
• 10 Cobey S, Larremore DB, Grad YH. et al. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nat Rev Immunol 2021; DOI: 10.1038/s41577-021-00544-9.
• 11 S2k-Leitlinie zur SARS-CoV-2, COVID-19 und (Früh-)Rehabilitation. Langversion – 2020 AWMF Registernummer: 080–008. (Stand: 1. November 2020) (last accessed on 3 March 2021) https://www.awmf.org/uploads/tx_szleitlinien/080-008l_S2k_SARS-CoV-2_COVID-19_und__Früh-__Rehabilitation_2020-11.pdf